Targeting arginine metabolism pathway to treat arginine-dependent cancers

Cancer Letters

Volumn 364, Issue 1, 2015, Pages 1-7

  Qiu, Fuming ^a   Huang, Jian ^a   Sui, Meihua ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Arginase I; Arginine deiminase; Arginine deprivation; Argininosuccinate synthase 1; PEGylation

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE 1; ARGININE; ARGININE DEIMINASE; ARGININOSUCCINATE SYNTHASE; ARGININOSUCCINATE SYNTHASE 1; CAPECITABINE; DEXAMETHASONE; DOXORUBICIN; OXALIPLATIN; PEGARGIMINASE; PEMETREXED; RECOMBINANT HUMAN ARGINASE I POLYETHYLENE GLYCOL; UNCLASSIFIED DRUG;

AAS1 GENE; ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; AUTOPHAGY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; GENE; GENE EXPRESSION; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OPEN READING FRAME; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN METABOLISM; PROTEIN TARGETING; SHORT SURVEY; SMALL CELL LUNG CANCER; SURVIVAL TIME; TUMOR GROWTH; METABOLISM; NEOPLASMS; PATHOLOGY;

ARGININE; CELL DEATH; HUMANS; NEOPLASMS;

EID: 84929654896     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.04.020     Document Type: Review

References (84)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Zhang Y., Yang J.M. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention. Cancer Biol. Ther 2013, 14:81-89.
3. Morris S.M. Arginine metabolism: boundaries of our knowledge. J. Nutr 2007, 137:1602S-1609S.
4. Fay M.M., Clegg J.M., Uchida K.A., Powers M.A., Ullman K.S. Enhanced arginine methylation of programmed cell death 4 protein during nutrient deprivation promotes tumor cell viability. J. Biol. Chem 2014, 289:17541-17552.
5. Morettin A., Baldwin R.M., Cote J. Arginine methyltransferases as novel therapeutic targets for breast cancer. Mutagenesis 2015, 30:177-189.
6. Rath M., Muller I., Kropf P., Closs E.I., Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front. Immunol 2014, 5:532.
7. Haines R.J., Pendleton L.C., Eichler D.C. Argininosuccinate synthase: at the center of arginine metabolism. Int. J. Biochem. Mol. Biol 2011, 2:8-23.
8. Dillon B.J., Prieto V.G., Curley S.A., Ensor C.M., Holtsberg F.W., Bomalaski J.S., et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004, 100:826-833.
9. Phillips M.M., Sheaff M.T., Szlosarek P.W. Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res. Treat 2013, 45:251-262.
10. Feun L.G., Kuo M.T., Savaraj N. Arginine deprivation in cancer therapy. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18:78-82.
11. Synakiewicz A., Stachowicz-Stencel T., Adamkiewicz-Drozynska E. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials. Expert Opin. Investig. Drugs 2014, 23:1517-1529.
12. Yeatman T.J., Risley G.L., Brunson M.E. Depletion of dietary arginine inhibits growth of metastatic tumor. Arch. Surg 1991, 126:1376-1381. discussion 1381-1372.
13. Gonzalez G.G., Byus C.V. Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res 1991, 51:2932-2939.
14. Gilroy E. The influence of arginine upon the growth rate of a transplantable tumour in the mouse. Biochem. J. 1930, 24:589-595.
15. Komada Y., Zhang X.L., Zhou Y.W., Ido M., Azuma E. Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase. Int. J. Hematol 1997, 65:129-141.
16. Gong H., Zolzer F., von Recklinghausen G., Rossler J., Breit S., Havers W., et al. Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem. Biophys. Res. Commun 1999, 261:10-14.
17. Gong H., Zolzer F., von Recklinghausen G., Havers W., Schweigerer L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 2000, 14:826-829.
18. Noh E.J., Kang S.W., Shin Y.J., Choi S.H., Kim C.G., Park I.S., et al. Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int. J. Cancer 2004, 112:502-508.
19. Shen L.J., Beloussow K., Shen W.C. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 2006, 231:30-35.
20. Ni Y., Schwaneberg U., Sun Z.H. Arginine deiminase, a potential anti-tumor drug. Cancer Lett 2008, 261:1-11.
21. Izzo F., Marra P., Beneduce G., Castello G., Vallone P., De Rosa V., et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J. Clin. Oncol 2004, 22:1815-1822.
22. Cheng P.N., Lam T.L., Lam W.M., Tsui S.M., Cheng A.W., Lo W.H., et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007, 67:309-317.
23. Ascierto P.A., Scala S., Castello G., Daponte A., Simeone E., Ottaiano A., et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J. Clin. Oncol 2005, 23:7660-7668.
24. Kim R.H., Coates J.M., Bowles T.L., McNerney G.P., Sutcliffe J., Jung J.U., et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009, 69:700-708.
25. Morrow K., Hernandez C.P., Raber P., Del Valle L., Wilk A.M., Majumdar S., et al. Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia 2013, 27:569-577.
26. Anderson G.M., Freytag S.O. Synergistic activation of a human promoter in vivo by transcription factor Sp1. Mol. Cell. Biol 1991, 11:1935-1943.
27. Tsai W.B., Aiba I., Lee S.Y., Feun L., Savaraj N., Kuo M.T. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol. Cancer Ther 2009, 8:3223-3233.
28. Szlosarek P.W., Klabatsa A., Pallaska A., Sheaff M., Smith P., Crook T., et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin. Cancer Res 2006, 12:7126-7131.
29. Delage B., Luong P., Maharaj L., O'Riain C., Syed N., Crook T., et al. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis 2012, 3:e342.
30. Syed N., Langer J., Janczar K., Singh P., Lo Nigro C., Lattanzio L., et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 2013, 4:e458.
31. Huang H.Y., Wu W.R., Wang Y.H., Wang J.W., Fang F.M., Tsai J.W., et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin. Cancer Res 2013, 19:2861-2872.
32. Guei T.R., Liu M.C., Yang C.P., Su T.S. Identification of a liver-specific cAMP response element in the human argininosuccinate synthetase gene. Biochem. Biophys. Res. Commun 2008, 377:257-261.
33. Karlberg T., Collins R., van den Berg S., Flores A., Hammarstrom M., Hogbom M., et al. Structure of human argininosuccinate synthetase. Acta Crystallogr. D Biol. Crystallogr 2008, 64:279-286.
34. Allen M.D., Luong P., Hudson C., Leyton J., Delage B., Ghazaly E., et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res 2014, 74:896-907.
35. Qiu F., Chen Y.R., Liu X., Chu C.Y., Shen L.J., Xu J., et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci. Signal 2014, 7:ra31.
36. Lagarde S.M., Ver Loren van Themaat P.E., Moerland P.D., Gilhuijs-Pederson L.A., Ten Kate F.J., Reitsma P.H., et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann. Surg. Oncol 2008, 15:3459-3470.
37. Huang C.C., Tsai S.T., Kuo C.C., Chang J.S., Jin Y.T., Chang J.Y., et al. Arginine deprivation as a new treatment strategy for head and neck cancer. Oral Oncol 2012, 48:1227-1235.
38. Yoon C.Y., Shim Y.J., Kim E.H., Lee J.H., Won N.H., Kim J.H., et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int. J. Cancer 2007, 120:897-905.
39. Szlosarek P.W., Steele J.P., Sheaff M.T., Avril N.E., Szyszko T., Ellis S., et al. A randomised phase II trial of pegylated arginine deiminase (ADI-PEG20) in patients with malignant pleural mesothelioma (MPM) 2013, World Conference on Lung Cancer, 2013 Oct 27-30; Sydney.
40. Feun L.G., Marini A., Walker G., Elgart G., Moffat F., Rodgers S.E., et al. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br. J. Cancer 2012, 106:1481-1485.
41. Lan J., Tai H.C., Lee S.W., Chen T.J., Huang H.Y., Li C.F. Deficiency in expression and epigenetic DNA Methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumour Biol 2014, 35:161-169.
42. Kobayashi E., Masuda M., Nakayama R., Ichikawa H., Satow R., Shitashige M., et al. Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol. Cancer Ther 2010, 9:535-544.
43. Nicholson L.J., Smith P.R., Hiller L., Szlosarek P.W., Kimberley C., Sehouli J., et al. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int. J. Cancer 2009, 125:1454-1463.
44. Bowles T.L., Kim R., Galante J., Parsons C.M., Virudachalam S., Kung H.J., et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int. J. Cancer 2008, 123:1950-1955.
45. Kim J.H., Yu Y.S., Kim D.H., Min B.H., Kim K.W. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol. Rep 2007, 18:1373-1377.
46. Kelly M.P., Jungbluth A.A., Wu B.W., Bomalaski J., Old L.J., Ritter G. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br. J. Cancer 2011, 106:324-332.
47. Yamauchi K., Komatsu T., Kulkarni A.D., Ohmori Y., Minami H., Ushiyama Y., et al. Glutamine and arginine affect Caco-2 cell proliferation by promotion of nucleotide synthesis. Nutrition 2002, 18:329-333.
48. Morris S.M. Enzymes of arginine metabolism. J. Nutr 2004, 134:2743S-2747S.
49. Horn F. The breakdown of arginine to citrulline by Bacillus pyocyaneus. Hoppe-Seyler's Z. Physiol. Chem 1933, 216:244-247.
50. Kraemer P.M., Defendi V., Hayflick L., Manson L.A. Mycoplasma (PPLO) strains with lytic activity for murine lymphoma cells in vitro. Proc. Soc. Exp. Biol. Med 1963, 112:381-387.
51. Kraemer P.M. Interaction of mycoplasma (Pplo) and murine lymphoma cell cultures: prevention of cell lysis by arginine. Proc. Soc. Exp. Biol. Med 1964, 115:206-212.
52. Takaku H., Takase M., Abe S., Hayashi H., Miyazaki K. In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer 1992, 51:244-249.
53. Miyazaki K., Takaku H., Umeda M., Fujita T., Huang W.D., Kimura T., et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res 1990, 50:4522-4527.
54. Miyazaki K., Mashima K., Kimura T., Huang W., Yano K., Ashida Y., et al. Growth inhibitors in serum, platelets, and normal and malignant tissues. Adv. Enzyme Regul 1987, 26:225-237.
55. Hahn R.G., Kenny G.E. Differences in arginine requirement for growth among arginine-utilizing Mycoplasma species. J. Bacteriol 1974, 117:611-618.
56. Holtsberg F.W., Ensor C.M., Steiner M.R., Bomalaski J.S., Clark M.A. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J. Control. Release 2002, 80:259-271.
57. Beloussow K., Wang L., Wu J., Ann D., Shen W.C. Recombinant arginine deiminase as a potential anti-angiogenic agent. Cancer Lett 2002, 183:155-162.
58. Bach S.J., Swaine D. The effect of arginase on the retardation of tumour growth. Br. J. Cancer 1965, 19:379-386.
59. Holley R.W. Evidence that a rat liver "inhibitor" of the synthesis of DNA in cultured mammalian cells is arginase. Biochim. Biophys. Acta 1967, 145:525-527.
60. Savoca K.V., Davis F.F., van Es T., McCoy J.R., Palczuk N.C. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia. Cancer Biochem. Biophys 1984, 7:261-268.
61. Dillon B.J., Holtsberg F.W., Ensor C.M., Bomalaski J.S., Clark M.A. Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med. Sci. Monit 2002, 8:BR248-BR253.
62. Tsui S.M., Lam W.M., Lam T.L., Chong H.C., So P.K., Kwok S.Y., et al. Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC). Cancer Cell Int 2009, 9:9.
63. Li L., Wang Y., Chen J., Cheng B., Hu J., Zhou Y., et al. An engineered arginase FC protein inhibits tumor growth in vitro and in vivo. Evid. Based Complement. Alternat. Med 2013, 2013:423129.
64. Ensor C.M., Holtsberg F.W., Bomalaski J.S., Clark M.A. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002, 62:5443-5450.
65. Park H., Lee J.B., Shim Y.J., Shin Y.J., Jeong S.Y., Oh J., et al. Arginine deiminase enhances MCF-7 cell radiosensitivity by inducing changes in the expression of cell cycle-related proteins. Mol. Cells 2008, 25:305-311.
66. Vynnytska-Myronovska B., Bobak Y., Garbe Y., Dittfeld C., Stasyk O., Kunz-Schughart L.A. Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation. Int. J. Cancer 2012, 130:2164-2175.
67. You M., Savaraj N., Wangpaichitr M., Wu C., Kuo M.T., Varona-Santos J., et al. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem. Biophys. Res. Commun 2010, 394:760-766.
68. Hernandez C.P., Morrow K., Lopez-Barcons L.A., Zabaleta J., Sierra R., Velasco C., et al. Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood 2010, 115:5214-5221.
69. Mauldin J.P., Zeinali I., Kleypas K., Woo J.H., Blackwood R.S., Jo C.H., et al. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Transl. Oncol 2012, 5:26-31.
70. Hsueh E.C., Knebel S.M., Lo W.H., Leung Y.C., Cheng P.N., Hsueh C.T. Deprivation of arginine by recombinant human arginase in prostate cancer cells. J. Hematol. Oncol 2012, 5:17.
71. Lam T.L., Wong G.K., Chow H.Y., Chong H.C., Chow T.L., Kwok S.Y., et al. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 2011, 24:366-376.
72. Glazer E.S., Piccirillo M., Albino V., Di Giacomo R., Palaia R., Mastro A.A., et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J. Clin. Oncol 2010, 28:2220-2226.
73. Yang T.S., Lu S.N., Chao Y., Sheen I.S., Lin C.C., Wang T.E., et al. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br. J. Cancer 2010, 103:954-960.
74. Ott P.A., Carvajal R.D., Pandit-Taskar N., Jungbluth A.A., Hoffman E.W., Wu B.W., et al. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest. New Drugs 2013, 31:425-434.
75. Szlosarek P.W., Luong P., Phillips M.M., Baccarini M., Stephen E., Szyszko T., et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J. Clin. Oncol 2013, 31:e111-e113.
76. Yau T., Cheng P.N., Chan P., Chan W., Chen L., Yuen J., et al. A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest. New Drugs 2013, 31:99-107.
77. Lam T.L., Wong G.K., Chong H.C., Cheng P.N., Choi S.C., Chow T.L., et al. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest. Cancer Lett 2009, 277:91-100.
78. Kim J.E., Kim S.Y., Lee K.W., Lee H.J. Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells. Br. J. Nutr 2009, 102:1469-1476.
79. Szlosarek P.W. Arginine deprivation and autophagic cell death in cancer. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:14015-14016.
80. Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E., et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 2015, 347:188-194.
81. Park I.S., Kang S.W., Shin Y.J., Chae K.Y., Park M.O., Kim M.Y., et al. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br. J. Cancer 2003, 89:907-914.
82. Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G., et al. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol. Rep 2011, 25:1495-1502.
83. Tsai W.B., Aiba I., Long Y., Lin H.K., Feun L., Savaraj N., et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res 2012, 72:2622-2633.
84. Long Y., Tsai W.B., Wangpaichitr M., Tsukamoto T., Savaraj N., Feun L.G., et al. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol. Cancer Ther 2013, 12:2581-2590.